Literature DB >> 20809263

Early-onset sensorineural hearing loss in Lassa fever.

T S Ibekwe1, P O Okokhere, D Asogun, F F Blackie, M M Nwegbu, K W Wahab, S A Omilabu, G O Akpede.   

Abstract

Lassa fever (LF) is a viral hemorrhagic disease which affects one-fourth to two million people annually with the fatality rate of about 10,000. It is associated with sensorineural hearing loss (SNHL) usually at the convalescent stage. Recently, cases of SNHL at the acute phase have been reported. This study was done to further investigate the incidence and features of SNHL in acute phase of LF. It is a prospective case-control study of LF patients seen with acute SNHL conducted between July 2007 and April 2009 at Irrua Specialist Teaching Hospital Nigeria. The diagnosis of acute LF was based on the clinical features and detection of IgM antibodies and/or positive Lassa virus-specific reverse transcriptase-polymerase chain reaction using primers S36+ and LVS 339 while SNHL was diagnosed clinically and confirmed with PTA and speech discrimination tests. Patients with other acute febrile illnesses were used as control. Statistical analysis was done using SPSS version 11 and Fisher's exact test while level of significance was set at p < 0.05. Out of the 37 confirmed cases of LF, 5 (13.5%) and none (0%) of the control developed early-onset SNHL (p = 0.03). Forty percent of the cases studied had negative IgM. The audiograms showed involvement at all frequency groups with pure tone average 65-85 dB and the speech discrimination 20-40%. The overall case fatality rate was 27.0%, and for early SNHL cases 60.0% (p > 0.05). The incidence of SNHL in LF infection is about 13.5% and could be a reflection of a worse disease process. There is possibility of direct viral invasion aside immunological reaction as a causative mechanism.

Entities:  

Mesh:

Year:  2010        PMID: 20809263     DOI: 10.1007/s00405-010-1370-4

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  32 in total

Review 1.  Management of Lassa fever in European countries.

Authors:  Natasha S Crowcroft
Journal:  Euro Surveill       Date:  2002-03

2.  Biochemistry of endolymph, perilymph and cerebrospinal fluid.

Authors:  E C DODDS
Journal:  J Laryngol Otol       Date:  1953-08       Impact factor: 1.469

3.  Lassa fever encephalopathy: Lassa virus in cerebrospinal fluid but not in serum.

Authors:  S Günther; B Weisner; A Roth; T Grewing; M Asper; C Drosten; P Emmerich; J Petersen; M Wilczek; H Schmitz
Journal:  J Infect Dis       Date:  2001-07-03       Impact factor: 5.226

4.  Update on emerging infections: news from the Centers for Disease Control and Prevention. Imported Lassa fever--New Jersey, 2004.

Authors:  Jacob W Ufberg; David J Karras
Journal:  Ann Emerg Med       Date:  2005-03       Impact factor: 5.721

5.  [Countermeasure against viral hemorrhagic fever at the border in Japan].

Authors:  Emiko Iwasaki
Journal:  Nihon Rinsho       Date:  2005-12

6.  A survey for antibodies to Lassa virus among health workers in Nigeria.

Authors:  M D Bajani; O Tomori; P E Rollin; T O Harry; N D Bukbuk; L Wilson; J E Childs; C J Peters; T G Ksiazek
Journal:  Trans R Soc Trop Med Hyg       Date:  1997 Jul-Aug       Impact factor: 2.184

Review 7.  Idiopathic sudden hearing loss: contradictory clinical evidence, placebo effects and high spontaneous recovery rate--where do we stand in assessing treatment outcomes?

Authors:  Robert P Finger; Antoniu O Gostian
Journal:  Acta Otolaryngol       Date:  2006-12       Impact factor: 1.494

8.  Clinical virology of Lassa fever in hospitalized patients.

Authors:  K M Johnson; J B McCormick; P A Webb; E S Smith; L H Elliott; I J King
Journal:  J Infect Dis       Date:  1987-03       Impact factor: 5.226

9.  Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings.

Authors:  J D Frame; J M Baldwin; D J Gocke; J M Troup
Journal:  Am J Trop Med Hyg       Date:  1970-07       Impact factor: 2.345

10.  Uses and abuses of hearing loss classification.

Authors:  J G Clark
Journal:  ASHA       Date:  1981-07
View more
  23 in total

1.  SAR studies of 4-acyl-1,6-dialkylpiperazin-2-one arenavirus cell entry inhibitors.

Authors:  Michael B Plewe; Landon R Whitby; Shibani Naik; Eric R Brown; Nadezda V Sokolova; Vidyasagar Reddy Gantla; Joanne York; Jack H Nunberg; Lihong Zhang; Birte Kalveram; Alexander N Freiberg; Dale L Boger; Greg Henkel; Ken McCormack
Journal:  Bioorg Med Chem Lett       Date:  2019-08-24       Impact factor: 2.823

Review 2.  Current small animal models for LASV hearing loss.

Authors:  Rachel A Sattler; Junki Maruyama; Nathan Y Shehu; Tomoko Makishima; Slobodan Paessler
Journal:  Curr Opin Virol       Date:  2019-08-31       Impact factor: 7.090

3.  Animal Model of Sensorineural Hearing Loss Associated with Lassa Virus Infection.

Authors:  Nadezhda E Yun; Shannon Ronca; Atsushi Tamura; Takaaki Koma; Alexey V Seregin; Kelly T Dineley; Milagros Miller; Rebecca Cook; Naoki Shimizu; Aida G Walker; Jeanon N Smith; Joseph N Fair; Nadia Wauquier; Bayon Bockarie; Sheik Humarr Khan; Tomoko Makishima; Slobodan Paessler
Journal:  J Virol       Date:  2015-12-30       Impact factor: 5.103

4.  CD4 T-cell depletion prevents Lassa fever associated hearing loss in the mouse model.

Authors:  Junki Maruyama; Rachel A Reyna; Megumi Kishimoto-Urata; Shinji Urata; John T Manning; Nantian Harsell; Rebecca Cook; Cheng Huang; Janko Nikolich-Zugich; Tomoko Makishima; Slobodan Paessler
Journal:  PLoS Pathog       Date:  2022-05-23       Impact factor: 7.464

5.  Clinical and laboratory predictors of Lassa fever outcome in a dedicated treatment facility in Nigeria: a retrospective, observational cohort study.

Authors:  Peter Okokhere; Andres Colubri; Chukwuemeka Azubike; Christopher Iruolagbe; Omoregie Osazuwa; Shervin Tabrizi; Elizabeth Chin; Sara Asad; Ehi Ediale; Mojeed Rafiu; Donatus Adomeh; Ikponmwosa Odia; Rebecca Atafo; Chris Aire; Sylvanus Okogbenin; Meike Pahlman; Beate Becker-Ziaja; Danny Asogun; Terrence Fradet; Ben Fry; Stephen F Schaffner; Christian Happi; George Akpede; Stephan Günther; Pardis C Sabeti
Journal:  Lancet Infect Dis       Date:  2018-03-06       Impact factor: 25.071

6.  Lassa fever: the challenges of curtailing a deadly disease.

Authors:  Titus Ibekwe
Journal:  Pan Afr Med J       Date:  2012-03-23

7.  Imported Case of Lassa Fever in Sweden With Encephalopathy and Sensorineural Hearing Deficit.

Authors:  Anna Grahn; Andreas Bråve; Martin Lagging; Leif Dotevall; David Ekqvist; Helena Hammarström; Helen Karlberg; Nina Lagerqvist; Martina Sansone; Anders Tegnell; Peter Ulleryd; Marie Studahl
Journal:  Open Forum Infect Dis       Date:  2016-09-20       Impact factor: 3.835

8.  Mouse Model of Neurological Complications Resulting from Encephalitic Alphavirus Infection.

Authors:  Shannon E Ronca; Jeanon Smith; Takaaki Koma; Magda M Miller; Nadezhda Yun; Kelly T Dineley; Slobodan Paessler
Journal:  Front Microbiol       Date:  2017-02-07       Impact factor: 5.640

9.  The sensitivity and specificity of Lassa virus IgM by ELISA as screening tool at early phase of Lassa fever infection.

Authors:  Titus S Ibekwe; Maxwell M Nwegbu; Daniel Asogun; Donatus I Adomeh; Peter O Okokhere
Journal:  Niger Med J       Date:  2012-10

10.  Potent inhibition of arenavirus infection by a novel fusion inhibitor.

Authors:  Brian B Gowen; Shibani Naik; Jonna B Westover; Eric R Brown; Vidyasagar R Gantla; Alexandra Fetsko; Ashley L Dagley; Dallan J Blotter; Nicole Anderson; Ken McCormack; Greg Henkel
Journal:  Antiviral Res       Date:  2021-06-29       Impact factor: 10.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.